Bernie Bochner, MD

Attending Surgeon, Sir Murray Brennan Endowed Chair in Surgery, Memorial Sloan Kettering Cancer Center. #bladder #prostate #kidney #cancer Opinions are my own

[Bernie Bochner, MD @bbmdmsk]

Proud dad today watching my youngest present at @MSKCancerCenter General Surg Grand Rounds with the other 2025-2026 Surgical Scholars. Humbled by the efforts of their amazing mentors and program leads. @VStrongMD
Carol Morris
Jonathan Forsberg
Marty Weiser
@Jeffrey_Drebin

[Bernie Bochner, MD @bbmdmsk]

Great job @aghasemzadeh1 on this ASCO YIA. Terrific collaboration between Jeff Ravitch @juanosoriomd @RockefellerUniv @MSKCancerCenter to improve our understanding of the immune environment of #bladdercancer
@DrRosenbergMSK @eugene_pietzak

[Ali Ghasemzadeh, MD, PhD @aghasemzadeh1]

Deeply honored to have been awarded an ASCO Young Investigator Award @ConquerCancerFd. Grateful to my mentors @bbmdmsk and Dr. Jeffrey Ravetch for their guidance and support.

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Heading to #AUA26? Don’t miss the Clinical Trials in Progress (CTiP) session.

@bbmdmsk and I will be moderating a deep dive as presenters share the raw science and trial designs for the next generation of bladder cancer care - including novel ADCs, gene therapy, and intravesical drug-delivery systems.

Your questions and input could help shape these studies before they reach the finish line.

See you at the Learning Lab in The Square!

#Urology #BladderCancer #MedicalInnovation @AmerUrological

[Bernie Bochner, MD @bbmdmsk]

What a pleasure to have one of my favorite people ever to join us as the 2026 Whitmore Lecturer @UrologyMSK @MSKCancerCenter
Thank you Eila Skinner MD for sharing your insight about the future of urologic oncology. Truly the best!!
@easthamja @eugene_pietzak @bca_md @arihakimi

[Hunter L. Hasley, MD @hunterhasley]

Great learning today! Thank you so much for the program and excellent teaching @Olympus_Corp @bbmdmsk @DrJohnSfakianos @JoshMeeks

[Noah Frydenlund @NFryden]

Highly recommend this course to trainees. Performing a quality TURBT is an undepreciated skill that has major implications for our patients. The models are exceptional! @Olympus_Corp @JoshMeeks @bbmdmsk

[Bernie Bochner, MD @bbmdmsk]

TURBT is one of the most impt surgical skills in managing #bladdercancer

2026 course was another big success. Thank you @olympusamerica for your support

Incredible group of residents fellows and attendings there this year. Thx @JoshMeeks and John Sfakianos for helping teach

[Andrew Katims, MD MPH @DrAndrewKatims]

We showed urine cytology/utDNA is a better marker of MRD in high risk NMIBC and a 20% eradication of CIS from TUR alone. Important implications for BCG unresponsive trials @UrologyMSK @eugene_pietzak @MaxKates @bbmdmsk @predicine

[Bernie Bochner, MD @bbmdmsk]

This study does not rule out the importance of the PLND for bladder cancer patients
Devil is always in the details

[Bernie Bochner, MD @bbmdmsk]

Not true. RC and a thorough PLND cures about 1/3 of node + bladderCA pts with surgery ALONE. S1011 enrolled relatively low risk pts (their control performed 10% better than designed) and expected an unrealistically large benefit from the ePLND (10% ⬆️3 yr RFS)=poor design.

[Drew Moghanaki @DrewMoghanaki]

Can we please put to rest the idea that treating lymph nodes helps patients with cancer live longer? Once again, we see no meaningful benefit and only harms—this time in a phase III RCT for bladder cancer. @QuadShotNews https://t.co/jT9UWVzn8p

[Bernie Bochner, MD @bbmdmsk]

COMPLICATIONS: S1011 reported the highest gr3-5 comp rate of any published cystectomy series, 2x higher than most contemp surgical RCTs (44% in the control arm!). A German multicent trial found appr 1/2 the Gr3-5 complic rate and NO diff in morb or mortality with ePLND v sPLND

[Bernie Bochner, MD @bbmdmsk]

@MaxKates Very impt point @MaxKates The benefit of IO + BCG upfront is a very limited improvement in preventing non-progressive, non-lethal HG tumors. The toxicity and financial costs are high. My opinion is start with BCG and reassess the need for combo rx in the non responders

[Yash Khandwala, MD @YashKhandwalaMD]

New data on outcomes after consolidative nephrectomy published in EU Oncology!

Our findings suggest that a major pathologic response after ICI therapy for metastatic RCC is associated with long PFS and OS.

Full study here: https://t.co/o8gLOlkYFZ

[Bernie Bochner, MD @bbmdmsk]

Massive advance for patients with MIBC.

[Jonathan Rosenberg MD @DrRosenbergMSK]

Big news- FDA approves EV/Pembro for patients with MIBC who are cisplatin ineligible! The needle moves. Great news for patients! https://t.co/FKo4OXqSJd @bbmdmsk @Dr_Aggen @shilpaonc @PGrivasMDPhD @DrChoueiri @montypal @apolo_andrea

[David H Aggen, MD PhD @Dr_Aggen]

🚀 Exciting advances in NMIBC at @MSKCancerCenter led by @UrologyMSK

🚨 Pragmatic trial for BCG-refractory NMIBC
Led by Eugene Pietzak (@eugene_pietzak) — Trial #25-069 / NCT06929286
https://t.co/F5DuW99AQu
https://t.co/GZAW6CeR8u

🚨 CD40 Agonist Trial for BCG-unresponsive NMIBC
Led by Bernie Bochner (@bbmdmsk) A shining example of bench to bedside medicine co-led by @juanosoriomd Trial #21-314 / NCT05126472.
https://t.co/2oWyfk5iwf
https://t.co/U4MeRXS0SL

Proud work from @urologymsk @MSKCancerCenter @BladderCancerUS

[David H Aggen, MD PhD @Dr_Aggen]

🚨 New trial options at @MSKCC for advanced bladder cancer after EV+P.

• HER2-targeted ADC: https://t.co/SERUMoBXZr (Disitamab Vedotin)
• TROP2-ADC: https://t.co/sApX2LHNVv (Datopotomab Deruxtecan)
• Nectin-4-ADC: https://t.co/QmYfgPk5eM (“Nectin-4 targeted ADCs”)
• Pan-tumor CDH6-ADC: https://t.co/H91uRg104O (Raludotatug Deruxtecan)

@MSK_Urology @MSK_DeptOfMed @MSKCC #BladderCancer #ClinicalTrials

[Bernie Bochner, MD @bbmdmsk]

Amazing night watching @rachel_bochner opening at @TheaterGramercy in #NYC

So good. Congrats Rachel 👏🏻👏🏻🫶🏻🫶🏻

[Nick Pickersgill, MD @NickPickersgill]

Our new study finds biparametric MRI offers diagnostic performance similar to multiparametric MRI for suspected prostate cancer, aligning with the recent PRIME trial results. Pros: shorter scan time, omitting contrast, lower cost.

https://t.co/ODEdWV0Lgg

[Bernie Bochner, MD @bbmdmsk]

@ColumbiaUrology @shah_ojas @ColumbiaMed @Endo_Society @AmerUrological Congrats Ojas. Great choice for Columbia.

[Bernie Bochner, MD @bbmdmsk]

@rachel_bochner Amazing work Rachel @rachel_bochner
🫶🏻👏🏻👏🏻👏🏻🫶🏻